SEOUL (Reuters) -South Korea’s drug watchdog said on Tuesday it would seek information from relevant companies after U.S. President Donald Trump linked the use of Tylenol by pregnant women to autism, a claim that is unsupported by scientific evidence. The drug regulator said it would review the opinions and documents provided by the companies. On […]
Health
South Korea’s drug watchdog to review U.S. Tylenol claim
Audio By Carbonatix
SEOUL (Reuters) -South Korea’s drug watchdog said on Tuesday it would seek information from relevant companies after U.S. President Donald Trump linked the use of Tylenol by pregnant women to autism, a claim that is unsupported by scientific evidence.
The drug regulator said it would review the opinions and documents provided by the companies.
On Monday, Trump also linked autism to childhood vaccine use.
“Since the U.S. government’s announcement contained little substance, we have no additional comments,” South Korea’s food and drug safety ministry said on Wednesday.
“However, we plan to request relevant papers and data from paracetamol importers and manufacturers.”
After Trump linked paracetamol to autism, international health agencies reaffirmed it was safe to use during pregnancy.
The World Health Organization said there was no conclusive scientific evidence linking paracetamol use during pregnancy to autism.
The European Medicines Agency said available evidence had found no such link and advised use of the lowest effective doses of the drug according to the frequency needed.
(Reporting by Hyunjoo Jin and Heekyong Yang; Editing by Clarence Fernandez and Thomas Derpinghaus)